|
1) Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomaized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metasta-tic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26: 620-5
|
|
|
|
2) Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472-80
|
|
|
|
|
|
3) Gastrointestinal Stromal Tumor Meta-Analysis Group. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1, 640 patients. J Clin Oncol. 2010; 28: 1247-53
|
|
|
|
|
|
4) Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009; 27: 3141-7
|
|
|
|
|
|
5) Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007; 25: 1107-13
|
|
|
|
|
|
6) Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010; 11: 942-9
|
|
|
|
|
|
7) Ray-Coquard IL, Bui BN, Adenis A, et al. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment. J Clin Oncol. 2010; 28 (suppl); 706S
|
|
|
|
|
|
8) Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006; 66: 8715-21
|
|
|
|
|
|
9) Benjamin RS, Schöffski P, Hartmann JT, et al. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol. 2011; 68: 69-77
|
|
|
|
|
|
10) Montemurro M, Schöffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. 2009; 45: 2293-7
|
|
|
|
|
|
11) Reichardt P, Blay J, Gelderblom H, et al. Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3. J Clin Oncol. 2010; 28 (suppl); 702S
|
|
|
|
|
|
12) Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011; 129: 245-55
|
|
|
|
|
|
13) Demetri G. A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). J Clin Oncol. 2011; 29 (suppl); 606S
|
|
|
|
|
|
14) Dematteo RP, Ballman KV, Antonescu CR, et al. American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stroma ltumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373: 1097-104
|
|
|
|
|
|
15) Casali PG and Blay JY. On behalf of the ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (Suppl. 5): v98–v102
|
|
|
|
|
|
16) Joensuu A. Tweleve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randamized trial (SSGXVIII/AIO). J Clin Oncol. 2011; 29 (suppl); 775S
|
|
|
|
|
|
17) Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol. 2006; 93: 304-11
|
|
|
|
|
|
18) Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006; 24: 2325-31
|
|
|
|
|
|
19) DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007; 245: 347-52
|
|
|
|
|
|
20) Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007; 245: 341-6
|
|
|
|
|
|
21) Sym SJ, Ryu MH, Lee JL, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol. 2008; 98: 27-33
|
|
|
|
|
|
22) Blesius A, Cassier PA, Bertucci F, et al. Neoaduvant imatinib in patienst with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer. 2011; 11: 72
|
|
|
|
|